{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:27:47Z","timestamp":1761870467737,"version":"build-2065373602"},"reference-count":57,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2010,6,1]],"date-time":"2010-06-01T00:00:00Z","timestamp":1275350400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2010,6,1]],"date-time":"2010-06-01T00:00:00Z","timestamp":1275350400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2010,6]]},"DOI":"10.3816\/clml.2010.s.004","type":"journal-article","created":{"date-parts":[[2010,6,8]],"date-time":"2010-06-08T21:18:41Z","timestamp":1276031921000},"page":"S27-S33","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"S1","title":["Role of CD20 Monoclonal Antibodies in Previously Untreated Chronic Lymphocytic Leukemia"],"prefix":"10.3816","volume":"10","author":[{"given":"Sameer A.","family":"Parikh","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William G.","family":"Wierda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.3816\/CLML.2010.s.004_bib1","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1056\/NEJMoa011795","article-title":"CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma","volume":"346","author":"Coiffier","year":"2002","journal-title":"N Engl J Med"},{"key":"10.3816\/CLML.2010.s.004_bib2","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1182\/blood.V90.6.2188","article-title":"IDEC-C2B8 (rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma","volume":"90","author":"Maloney","year":"1997","journal-title":"Blood"},{"key":"10.3816\/CLML.2010.s.004_bib3","first-page":"17","article-title":"CD20: a gene in search of a function","volume":"27","author":"Riley","year":"2000","journal-title":"Semin Oncol"},{"key":"10.3816\/CLML.2010.s.004_bib4","doi-asserted-by":"crossref","first-page":"7359","DOI":"10.1038\/sj.onc.1206939","article-title":"Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance","volume":"22","author":"Smith","year":"2003","journal-title":"Oncogene"},{"key":"10.3816\/CLML.2010.s.004_bib5","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1182\/blood.V84.8.2457.2457","article-title":"Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma","volume":"84","author":"Maloney","year":"1994","journal-title":"Blood"},{"key":"10.3816\/CLML.2010.s.004_bib6","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.1200\/JCO.1998.16.8.2825","article-title":"Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program","volume":"16","author":"McLaughlin","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLML.2010.s.004_bib7","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1200\/JCO.2000.18.2.317","article-title":"European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma","volume":"18","author":"Foran","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLML.2010.s.004_bib8","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1034\/j.1600-0609.2002.02786.x","article-title":"Standard-dose anti-CD20 antibody rituximab has efficacy in chronic lymphocytic leukaemia: results from a Nordic multicentre study","volume":"69","author":"Itala","year":"2002","journal-title":"Eur J Haematol"},{"key":"10.3816\/CLML.2010.s.004_bib9","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1111\/j.1600-0609.1999.tb01725.x","article-title":"IDEC-C2B8 anti-CD20 (rituximab) immunotherapy in patients with low-grade non-Hodgkin's lymphoma and lymphoproliferative disorders: evaluation of response on 48 patients","volume":"62","author":"Nguyen","year":"1999","journal-title":"Eur J Haematol"},{"key":"10.3816\/CLML.2010.s.004_bib10","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1200\/JCO.2003.09.027","article-title":"Single-agent rituximab as first-line and maintenance treatment for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: a phase II trial of the Minnie Pearl Cancer Research Network","volume":"21","author":"Hainsworth","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLML.2010.s.004_bib11","article-title":"Single agent rituxan in early stage chronic lymphocytic leukemia","volume":"98","author":"Thomas","year":"2001","journal-title":"Blood"},{"key":"10.3816\/CLML.2010.s.004_bib12","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1002\/ajh.2830400404","article-title":"Reduced expression of CD20 antigen as a characteristic marker for chronic lymphocytic leukemia","volume":"40","author":"Almasri","year":"1992","journal-title":"Am J Hematol"},{"key":"10.3816\/CLML.2010.s.004_bib13","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1136\/jcp.51.5.364","article-title":"Levels of expression of CD19 and CD20 in chronic B cell leukaemias","volume":"51","author":"Ginaldi","year":"1998","journal-title":"J Clin Pathol"},{"key":"10.3816\/CLML.2010.s.004_bib14","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1053\/sonc.2002.30156","article-title":"Rituximab: mechanism of action and resistance","volume":"29","author":"Maloney","year":"2002","journal-title":"Semin Oncol"},{"key":"10.3816\/CLML.2010.s.004_bib15","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1038\/sj.thj.6200119","article-title":"Variability in B-cell antigen expression: implications for the treatment of B-cell lymphomas and leukemias with monoclonal antibodies","volume":"2","author":"Rossmann","year":"2001","journal-title":"Hematol J"},{"key":"10.3816\/CLML.2010.s.004_bib16","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1182\/blood-2002-06-1639","article-title":"Circulating CD20 is detectable in the plasma of patients with chronic lymphocytic leukemia and is of prognostic significance","volume":"101","author":"Manshouri","year":"2003","journal-title":"Blood"},{"key":"10.3816\/CLML.2010.s.004_bib17","doi-asserted-by":"crossref","first-page":"2165","DOI":"10.1200\/JCO.2001.19.8.2165","article-title":"Rituximab dose-escalation trial in chronic lymphocytic leukemia","volume":"19","author":"O\u2019Brien","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLML.2010.s.004_bib18","doi-asserted-by":"crossref","first-page":"2153","DOI":"10.1200\/JCO.2001.19.8.2153","article-title":"Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity","volume":"19","author":"Byrd","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLML.2010.s.004_bib19","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1182\/blood-2002-04-1258","article-title":"Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712)","volume":"101","author":"Byrd","year":"2003","journal-title":"Blood"},{"key":"10.3816\/CLML.2010.s.004_bib20","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1182\/blood.V114.22.539.539","article-title":"Treatment with fludarabine and rituximab produces extended overall survival (OS) and progression-free survival (PFS) in chronic lymphocytic leukemia (CLL) without increased risk of second malignancy: long-term follow up of CALGB Study 9712","volume":"114","author":"Woyach","year":"2009","journal-title":"Blood"},{"key":"10.3816\/CLML.2010.s.004_bib21","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1182\/blood.V114.22.3428.3428","article-title":"An open-label phase II study to investigate the safety and efficacy of rituximab plus chlorambucil in previously untreated patients with CD20-positive B-cell chronic lymphocytic leukaemia (CLL)","volume":"114","author":"Hillmen","year":"2009","journal-title":"Blood"},{"key":"10.3816\/CLML.2010.s.004_bib22","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1182\/blood.V114.22.205.205","article-title":"Bendamustine combined with rituximab (BR) in first-line therapy of advanced CLL: A multicenter phase II trial of the German CLL Study Group (GCLLSG)","volume":"114","author":"Fischer","year":"2009","journal-title":"Blood"},{"key":"10.3816\/CLML.2010.s.004_bib23","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.1002\/cncr.23824","article-title":"Early treatment of high-risk chronic lymphocytic leukemia with alemtuzumab and rituximab","volume":"113","author":"Zent","year":"2008","journal-title":"Cancer"},{"key":"10.3816\/CLML.2010.s.004_bib24","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1182\/blood.V114.22.208.208","article-title":"Frontline combined chemoimmunotherapy with fludarabine, cyclophosphamide, alemtuzumab and rituximab (CFAR) in high-risk chronic lymphocytic leukemia","volume":"114","author":"Parikh","year":"2009","journal-title":"Blood"},{"key":"10.3816\/CLML.2010.s.004_bib25","doi-asserted-by":"crossref","first-page":"4079","DOI":"10.1200\/JCO.2005.12.051","article-title":"Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia","volume":"23","author":"Keating","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLML.2010.s.004_bib26","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1182\/blood-2008-02-140582","article-title":"Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia","volume":"112","author":"Tam","year":"2008","journal-title":"Blood"},{"key":"10.3816\/CLML.2010.s.004_bib27","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1182\/blood.V114.22.535.535","volume":"114","author":"Hallek","year":"2009","journal-title":"Blood"},{"key":"10.3816\/CLML.2010.s.004_bib28","doi-asserted-by":"crossref","first-page":"194a","DOI":"10.1182\/blood.V110.11.628.628","article-title":"Combined cyclophosphamide, fludarabine, alemtuzumab, and rituximab (CFAR), an active frontline regimen for high-risk patients with CLL","volume":"110","author":"Wierda","year":"2007","journal-title":"Blood"},{"key":"10.3816\/CLML.2010.s.004_bib29","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V106.11.2117.2117","article-title":"FCR-3 as frontline therapy for patients with chronic lymphocytic leukemia (CLL)","volume":"106","author":"O\u2019Brien","year":"2005","journal-title":"Blood"},{"key":"10.3816\/CLML.2010.s.004_bib30","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1182\/blood-2006-07-033274","article-title":"Combination chemoimmunotherapy with pentostatin, cyclophosphamide, and rituximab shows significant clinical activity with low accompanying toxicity in previously untreated B chronic lymphocytic leukemia","volume":"109","author":"Kay","year":"2007","journal-title":"Blood"},{"key":"10.3816\/CLML.2010.s.004_bib31","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1200\/JCO.2008.17.2619","article-title":"Chemoimmunotherapy with low-dose fludarabine and cyclophosphamide and high dose rituximab in previously untreated patients with chronic lymphocytic leukemia","volume":"27","author":"Foon","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLML.2010.s.004_bib32","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.leukres.2009.07.008","article-title":"Fludarabine, cyclophosphamide, mitoxantrone plus rituximab (FCM-R) in frontline CLL <70 Years","volume":"34","author":"Faderl","year":"2010","journal-title":"Leuk Res"},{"key":"10.3816\/CLML.2010.s.004_bib33","doi-asserted-by":"crossref","first-page":"4578","DOI":"10.1200\/JCO.2009.22.0442","article-title":"Rituximab, fludarabine, cyclophosphamide, and mitoxantrone: a new, highly active chemoimmunotherapy regimen for chronic lymphocytic leukemia","volume":"27","author":"Bosch","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLML.2010.s.004_bib34","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1182\/blood-2004-03-0796","article-title":"Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective comparative analysis of CALGB 9712 and CALGB 9011","volume":"105","author":"Byrd","year":"2005","journal-title":"Blood"},{"key":"10.3816\/CLML.2010.s.004_bib35","doi-asserted-by":"crossref","first-page":"3115","DOI":"10.1182\/blood-2002-03-0972","article-title":"Phase 2 study of a combined immunochemotherapy using rituximab and fludarabine in patients with chronic lymphocytic leukemia","volume":"100","author":"Schulz","year":"2002","journal-title":"Blood"},{"key":"10.3816\/CLML.2010.s.004_bib36","doi-asserted-by":"crossref","first-page":"2836","DOI":"10.1182\/blood.V94.8.2836.420k35_2836_2843","article-title":"In vitro evaluation of fludarabine in combination with cyclophosphamide and\/or mitoxantrone in B-cell chronic lymphocytic leukemia","volume":"94","author":"Bellosillo","year":"1999","journal-title":"Blood"},{"key":"10.3816\/CLML.2010.s.004_bib37","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1200\/JCO.2001.19.5.1414","article-title":"Results of the fludarabine and cyclophosphamide combination regimen in chronic lymphocytic leukemia","volume":"19","author":"O\u2019Brien","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLML.2010.s.004_bib38","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1182\/blood.V112.11.325.325","volume":"112","author":"Hallek","year":"2008","journal-title":"Blood"},{"key":"10.3816\/CLML.2010.s.004_bib39","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1200\/JCO.2005.04.3836","article-title":"Pentostatin, cyclophosphamide, and rituximab is an active, well-tolerated regimen for patients with previously treated chronic lymphocytic leukemia","volume":"24","author":"Lamanna","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLML.2010.s.004_bib40","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1182\/blood.V112.11.327.327","article-title":"Phase III trial of fludarabine, cyclophosphamide, and rituximab vs. pentostatin, cyclophosphamide, and rituximab in B-cell chronic lymphocytic leukemia","volume":"112","author":"Reynolds","year":"2008","journal-title":"Blood"},{"key":"10.3816\/CLML.2010.s.004_bib41","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s11523-008-0099-0","article-title":"Targeted therapy for chronic lymphocytic leukemia","volume":"4","author":"Quintas-Cardama","year":"2009","journal-title":"Target Oncol"},{"key":"10.3816\/CLML.2010.s.004_bib42","doi-asserted-by":"crossref","first-page":"2269","DOI":"10.1080\/10428190412331286096","article-title":"A pilot trial of rituximab and alemtuzumab combination therapy in patients with relapsed and\/or refractory chronic lymphocytic leukemia (CLL)","volume":"45","author":"Nabhan","year":"2004","journal-title":"Leuk Lymphoma"},{"key":"10.3816\/CLML.2010.s.004_bib43","first-page":"33","article-title":"Anti-CD20 antibody (IDEC-C2B8, rituximab) enhances efficacy of cytotoxic drugs on neoplastic lymphocytes in vitro: role of cytokines, complement, and caspases","volume":"87","author":"Chow","year":"2002","journal-title":"Haematologica"},{"key":"10.3816\/CLML.2010.s.004_bib44","first-page":"24","article-title":"Rituximab and high-dose methylprednisolone for the initial treatment of chronic lymphocytic leukemia is associated with promising clinical activity and minimal hematologic toxicity","volume":"112","author":"James","year":"2008","journal-title":"Blood"},{"key":"10.3816\/CLML.2010.s.004_bib45","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.ctrv.2005.05.007","article-title":"Tolerability and safety of rituximab (MabThera)","volume":"31","author":"Kimby","year":"2005","journal-title":"Cancer Treat Rev"},{"key":"10.3816\/CLML.2010.s.004_bib46","doi-asserted-by":"crossref","first-page":"202","DOI":"10.6004\/jnccn.2008.0017","article-title":"Infectious complications associated with immunomodulating monoclonal antibodies used in the treatment of hematologic malignancy","volume":"6","author":"Koo","year":"2008","journal-title":"J Natl Compr Canc Netw"},{"key":"10.3816\/CLML.2010.s.004_bib47","doi-asserted-by":"crossref","first-page":"4834","DOI":"10.1182\/blood-2008-10-186999","article-title":"Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project","volume":"113","author":"Carson","year":"2009","journal-title":"Blood"},{"key":"10.3816\/CLML.2010.s.004_bib48","doi-asserted-by":"crossref","first-page":"3823","DOI":"10.1016\/j.molimm.2007.06.151","article-title":"Mechanisms of killing by anti-CD20 monoclonal antibodies","volume":"44","author":"Glennie","year":"2007","journal-title":"Mol Immunol"},{"key":"10.3816\/CLML.2010.s.004_bib49","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1182\/asheducation-2007.1.226","article-title":"Follicular NHL: from antibodies and vaccines to graft-versus-lymphoma effects","author":"Maloney","year":"2007","journal-title":"Hematology (Am Soc Hematol Educ Program)"},{"key":"10.3816\/CLML.2010.s.004_bib50","doi-asserted-by":"crossref","first-page":"135","DOI":"10.3324\/haematol.2008.001628","article-title":"Anti-CD20 monoclonal antibodies \u2014 historical and future perspectives","volume":"95","author":"Lim","year":"2009","journal-title":"Haematologica"},{"key":"10.3816\/CLML.2010.s.004_bib51","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1182\/blood.V114.22.884.884","article-title":"Phase I study of RO5072759 (GA101) in relapsed\/refractory chronic lymphocytic leukemia","volume":"114","author":"Morschhauser","year":"2009","journal-title":"Blood"},{"key":"10.3816\/CLML.2010.s.004_bib52","doi-asserted-by":"crossref","first-page":"2868","DOI":"10.1158\/1078-0432.CCR-03-0493","article-title":"Characterization of a new humanized anti-CD20 monoclonal antibody, IMMU-106, and Its use in combination with the humanized anti-CD22 antibody, epratuzumab, for the therapy of non-Hodgkin's lymphoma","volume":"10","author":"Stein","year":"2004","journal-title":"Clin Cancer Res"},{"key":"10.3816\/CLML.2010.s.004_bib53","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1097\/01.cji.0000155050.03916.04","article-title":"Depletion of B cells by a humanized anti-CD20 antibody PRO70769 in Macaca fascicularis","volume":"28","author":"Vugmeyster","year":"2005","journal-title":"J Immunother"},{"key":"10.3816\/CLML.2010.s.004_bib54","doi-asserted-by":"crossref","first-page":"2738","DOI":"10.1182\/blood-2003-06-2031","article-title":"Antibody specificity controls in vivo effector mechanisms of anti-CD20 reagents","volume":"103","author":"Cragg","year":"2004","journal-title":"Blood"},{"key":"10.3816\/CLML.2010.s.004_bib55","doi-asserted-by":"crossref","first-page":"5486","DOI":"10.1182\/blood-2007-10-117671","article-title":"First clinical use of ofatumumab, a novel fully human anti-CD20 monoclonal antibody in relapsed or refractory follicular lymphoma: results of a phase 1\/2 trial","volume":"111","author":"Hagenbeek","year":"2008","journal-title":"Blood"},{"key":"10.3816\/CLML.2010.s.004_bib56","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1182\/blood.V114.22.207.207","article-title":"Ofatumumab combined with fludarabine and cyclophosphamide (O-FC) shows high activity in patients with previously untreated chronic lymphocytic leukemia (CLL): results from a randomized, multicenter, international, two-dose, parallel group, phase II trial","volume":"114","author":"Wierda","year":"2009","journal-title":"Blood"},{"key":"10.3816\/CLML.2010.s.004_bib57","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1182\/blood.V114.22.1704.1704","article-title":"Phase I study of RO5072759 (GA101) in patients with relapsed\/refractory CD20+ non-Hodgkin lymphoma (NHL)","volume":"114","author":"Salles","year":"2009","journal-title":"Blood"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265011700568?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265011700568?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:22:46Z","timestamp":1761870166000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265011700568"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,6]]},"references-count":57,"alternative-id":["S2152265011700568"],"URL":"https:\/\/doi.org\/10.3816\/clml.2010.s.004","relation":{},"ISSN":["2152-2650"],"issn-type":[{"type":"print","value":"2152-2650"}],"subject":[],"published":{"date-parts":[[2010,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Role of CD20 Monoclonal Antibodies in Previously Untreated Chronic Lymphocytic Leukemia","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.3816\/CLML.2010.s.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2010 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}